Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-09-10 pm EDT After market 07:00:10 pm
901.25 USD -0.77% Intraday chart for Eli Lilly and Company 902.30 +0.12%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Health Care Up on Defensive Bias -- Health Care Roundup DJ
Weight-loss market to see 16 new drugs by 2029, report estimates RE
Eli Lilly Says Efsitora Effective in Adults With Type 1 or 2 Diabetes in Phase 3 Trials MT
Lilly appoints insider as finance chief amid rising investments to boost capacity RE
The market burns its idols Our Logo
Eli Lilly Appoints New Finance Chief MT
Eli Lilly: in-house executive appointed CFO CF
Eli Lilly Appoints Lucas Montarce CFO MT
Eli Lilly Appoints Lucas Montarce as CFO MT
Eli Lilly and Co. Appoints Lucas Montarce as CFO CI
Eli Lilly and Co. Appoints Lucas Montarce as Executive Vice President and Member of the Executive Committee CI
Superluminal Medicines Inc. announced that it has received $120 million in funding from a group of investors CI
Are thematic ETFs useless? Our Logo
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
OrsoBio, Inc. announced that it has received $67 million in funding from a group of investors CI
Health Care Declines as Risk Aversion Weighs - Health Care Roundup DJ
Eli Lilly: agreements signed with Qiagen and Genetic Leap CF
Such a long wait Our Logo
Eli Lilly: positive results from weekly insulin trials CF
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday MT
Transcript : Eli Lilly and Company Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 07:45 AM
Eli Lilly Says Phase 3 Trials of Insulin Efsitora Alfa Achieve Primary Endpoint MT
Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa CI
How to find and check an Ozempic batch number RE
Qiagen Partners with Eli Lilly to Develop Testing Panel for Alzheimer's Disease MT
Chart Eli Lilly and Company
More charts
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Employees
43,000
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
901.25USD
Average target price
986.82USD
Spread / Average Target
+9.49%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Eli Lilly's Assurances on Key GLP-1 Drugs Should Ease Investor Concerns, UBS Says
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW